These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38444047)

  • 1. Design, synthesis, in silico molecular docking, and ADMET studies of quinoxaline-isoxazole-piperazine conjugates as EGFR-targeting agents.
    Ali MI; Thirukovela NS; Kumar GB; Dasari G; Badithapuram V; Manchal R; Bandari S
    Chem Biol Drug Des; 2024 Mar; 103(3):e14499. PubMed ID: 38444047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis,
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR
    Al-Wahaibi LH; Mohammed AF; Abdel Rahman FES; Abdelrahman MH; Gu X; Trembleau L; Youssif BGM
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2218602. PubMed ID: 37254958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Synthesis of Non-Covalent Imidazo[1,2-
    Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
    El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
    Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation.
    Alsaad HN; Al-Jasani BM; Mahmood AAR; Tahtamouni LH; Saleh KM; AlSakhen MF; Kanaan SI; Yasin SR
    Drug Dev Res; 2024 Aug; 85(5):e22231. PubMed ID: 38956926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
    O Aboelez M; Belal A; Xiang G; Ma X
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1196-1211. PubMed ID: 35470756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-
    Ismail MA; Abusaif MS; El-Gaby MSA; Ammar YA; Ragab A
    RSC Adv; 2023 Apr; 13(18):12589-12608. PubMed ID: 37101951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-allyl quinoxaline derivative exhibited potent and selective cytotoxicity through EGFR/VEGFR-mediated apoptosis: In vitro and in vivo studies.
    Nafie MS; Ali MA; Youssef MM
    J Biochem Mol Toxicol; 2024 Apr; 38(4):e23690. PubMed ID: 38493304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents.
    Abd El-Sattar NEA; El-Adl K; El-Hashash MA; Salama SA; Elhady MM
    Bioorg Chem; 2021 Oct; 115():105186. PubMed ID: 34314914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
    Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.
    Ragab FA; Eissa AAM; Fahim SH; Salem MA; Gamal MA; Nissan YM
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100029. PubMed ID: 33872414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
    Kumar A; Kumar B; Bhatia R
    Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.